Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer
The Lancet Oncology in conversation with
English - June 30, 2018 06:30 - 9 minutes - 6.8 MB - ★★★★★ - 1 ratingMedicine Health & Fitness Education cancer radiotherapy chemotherapy mrna Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Gender and cancer immunotherapy efficacy
Next Episode: Diffuse intrinsic pontine glioma
Bo Jan Noordman joins The Lancet Oncology to discuss the findings from his study of residual disease detection in oesophageal cancer.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv